🔎 Trials Near Me

Почетна › Беркитов лимфом › Јужна Дакота

Kliničke studije za Беркитов лимфом u državi Јужна Дакота

5 studija za Беркитов лимфом traži učesnike na lokacijama u državi Јужна Дакота.

Gradovi u državi Јужна Дакота

Zvanični tekst studije (na engleskom)

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

  • Sanford USD Medical Center - Sioux Falls, Sioux Falls
Тражи се учесникФаза 2
Узраст од 1 до 30 · Оба пола · Ажурирано 12. 11. 2026. · NCT04546399

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

  • Sanford Children's Hospital-Sanford Children's Specialty Clinic ( Site 1015), Sioux Falls
Тражи се учесникФаза 1/2
6 Months – 25 Years · Оба пола · Ажурирано 30. 10. 2026. · NCT06395103

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

  • Sanford USD Medical Center - Sioux Falls, Sioux Falls
Тражи се учесникФаза 2
365 Days · Оба пола · Ажурирано 27. 10. 2026. · NCT06317662

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

  • Sanford USD Medical Center - Sioux Falls, Sioux Falls
Тражи се учесникФаза 2
366 Days – 46 Years · Оба пола · Ажурирано 27. 10. 2026. · NCT06124157

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • Sanford USD Medical Center - Sioux Falls, Sioux Falls
Тражи се учесникФаза 3
365 Days – 25 Years · Оба пола · Ажурирано 25. 8. 2026. · NCT03959085

Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.